Zymeworks (ZYME) 25th Annual Needham Virtual Healthcare Conference summary

Strategic evolution and business model

• Transitioning from a traditional biotech to a diversified asset aggregator, combining internal R&D with asset acquisition and royalty aggregation strategies.

• Focused on disciplined capital allocation to maximize long-term shareholder value and reduce binary risk typical in biotech.

• Hybrid model leverages R&D to generate new assets and royalties, while investment activities target undervalued or overlooked opportunities.

• Recent leadership appointments aim to strengthen capital management, external partnering, and R&D execution.

• Strategy differentiates from traditional royalty aggregators by integrating scientific expertise and operational capabilities to unlock value in complex assets.

Financial position and capital allocation

• Secured $250 million in non-dilutive capital from Royalty Pharma, backed by a minority portion of future zanidatamab royalties.

• Strong cash position with over $270 million reported, excluding the Royalty Pharma transaction, and $440 million in near-term milestones expected.

• Announced a $125 million share repurchase program, with $62.5 million executed as of March, supporting shareholder returns.

• Revenue in 2025 projected at $106 million, a 40% increase year-over-year.

• Capital allocation prioritizes fully funding R&D, with excess capital directed to shareholder returns and strategic investments.

Pipeline and clinical progress

• Advancing clinical programs including ZW191 (folate receptor alpha ADC), ZW251 (GPC3 ADC), and IND submissions for 209 and 1528 expected this year.

• Focus on multispecific antibody and engineered cytokine platforms, with early-stage partnerships and out-licensing to support development.

• Seven presentations planned at AACR, including first public disclosure of the pan-RAS ADC portfolio.

• NaPi2b ADC program is phase I-ready, and immunology pipeline includes a phase I-ready IL-4/IL-33 bispecific.

• Pipeline expansion beyond oncology is anticipated, leveraging proprietary engineering capabilities.